Brain radiation plus chemo-immunotherapy for untreated NSCLC with stable brain metastases
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that has spread to the brain (at least one brain lesion larger than 5mm on MRI).
- You have not had any previous treatment for your lung cancer or brain metastases.
- Your tumor does not have changes in the EGFR, ALK, or ROS1 genes.
- You are at least 18 years old and feel well enough to carry out daily activities (KPS score 70 or higher).
- You do not have severe autoimmune diseases, active infections, or other uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radiation approach for people with small cell lung cancer that has spread to the brain. It combines whole-brain radiation that avoids the memory centers, followed by focused radiation to the tumors, while you also receive standard chemotherapy and immunotherapy.
This trial is for people with cancer that has spread to the brain (brain metastases). It tests a new approach where you start a systemic therapy (drugs that travel through your body) and later add focused radiation to the brain tumors, instead of treating them right away. The goal is to see if this sequence works well and avoids unnecessary side effects.
This trial tests a combination of focused radiation (stereotactic radiosurgery) and an oral targeted therapy called anlotinib for people with non-small cell lung cancer that has spread to the brain. It may offer a way to control brain metastases without more invasive procedures.
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
This Phase 2 trial tests a type of focused radiation (stereotactic radiosurgery, or SRS) for people with small cell lung cancer that has spread to the brain. It looks at whether this approach can treat brain metastases when the cancer has limited to a certain number of spots.
This study tests whether armatinib alone or combined with focused brain radiation (SRT) can control brain metastases from EGFR-mutated non-small cell lung cancer. It aims to improve outcomes for people with few, mostly low-symptom brain spots.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.